Unknown

Dataset Information

0

Edoxaban in patients with atrial fibrillation.

ABSTRACT: Edoxaban, a direct factor Xa inhibitor, was extensively studied in the prevention and treatment of venous thromboembolism and in patients with nonvalvular atrial fibrillation (AF). The aim of this review is to focus specifically on the efficacy and safety profile of edoxaban in patients with AF from preclinical development through the phase III trial that led to regulatory approval.

SUBMITTER: Eisen A 

PROVIDER: S-EPMC5942795 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Edoxaban in patients with atrial fibrillation.

Eisen Alon A   Ruff Christian T CT  

Therapeutic advances in cardiovascular disease 20160801 3

Edoxaban, a direct factor Xa inhibitor, was extensively studied in the prevention and treatment of venous thromboembolism and in patients with nonvalvular atrial fibrillation (AF). The aim of this review is to focus specifically on the efficacy and safety profile of edoxaban in patients with AF from preclinical development through the phase III trial that led to regulatory approval. ...[more]

Similar Datasets

Unknown Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation.
| S-EPMC8458830 | biostudies-literature
Unknown Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min.
| S-EPMC9299591 | biostudies-literature
Unknown Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation.
| S-EPMC6491445 | biostudies-literature
Unknown Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure.
| S-EPMC8332564 | biostudies-literature
Unknown Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice.
| S-EPMC8623093 | biostudies-literature
Proteomics myocardial tissue from atrial fibrillation patients
2018-11-22 | PXD006911 | Pride
Unknown Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
| S-EPMC6625115 | biostudies-literature
Unknown Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
| S-EPMC4889207 | biostudies-literature
Unknown An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.
| S-EPMC4422295 | biostudies-literature
Unknown Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
| S-EPMC6754569 | biostudies-literature